SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Tharimmune, Inc. (THAR) has a negative trailing P/E of -2.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -34.86%.
Criteria proven by this page:
- VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -2.9); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -34.86%).
- Trailing Earnings Yield -34.86% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Overall SharesGrow Score: 25/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — THAR
Valuation Multiples
P/E (TTM)-2.9
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.26
P/S Ratio0.00
EV/EBITDA-4.8
Per Share Data
EPS (TTM)$-1.12
Book Value / Share$12.42
Revenue / Share$0.00
FCF / Share$-0.50
Yields & Fair Value
Earnings Yield-34.86%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-23.5 |
0.00 |
-22.09 |
0.00 |
- |
| 2020 |
-14.8 |
-0.25 |
-9.64 |
0.00 |
- |
| 2021 |
-17.9 |
1.04 |
-8.44 |
0.00 |
- |
| 2022 |
-0.5 |
0.00 |
0.80 |
0.00 |
- |
| 2023 |
-0.1 |
0.00 |
0.07 |
0.00 |
- |
| 2024 |
-0.2 |
0.00 |
2.01 |
0.00 |
- |
| 2025 |
-2.7 |
0.03 |
0.24 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-55.56 |
$0.00 |
$-1.53M |
- |
| 2020 |
$-88.05 |
$0.00 |
$-2.42M |
- |
| 2021 |
$-72.81 |
$0.00 |
$-2.21M |
- |
| 2022 |
$-280.77 |
$0.00 |
$-8.47M |
- |
| 2023 |
$-107.08 |
$0.00 |
$-9.32M |
- |
| 2024 |
$-9.41 |
$0.00 |
$-12.2M |
- |
| 2025 |
$-1.12 |
$0.00 |
$-35.92M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.75 |
$-0.75 – $-0.75 |
$0.00 |
$0.00 – $0.00 |
1 |
| 2027 |
$-0.90 |
$-0.90 – $-0.90 |
$0.00 |
$0.00 – $0.00 |
1 |
| 2028 |
$-1.05 |
$-1.05 – $-1.05 |
$0.00 |
$0.00 – $0.00 |
1 |
